A citation-based method for searching scientific literature

Yonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, Jessica R Flynn, Joseph Montecalvo, Natasha Rekhtman, Darragh Halpenny, Andrew J Plodkowski, Stephanie L Wu, Mark G Kris, Paul K Paik, Gregory J Riely, Helena A Yu, Charles M Rudin, Matthew D Hellmann, Josiah D Land, Larry W Buie, Glenn Heller, Piro Lito, Rona Yaeger, Alexander Drilon, Dazhi Liu, Bob T Li, Michael Offin. Br J Cancer 2022
Times Cited: 2







List of co-cited articles
9 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
Marcelo V Negrao, Victoria M Raymond, Richard B Lanman, Jacqulyne P Robichaux, Junqin He, Monique B Nilsson, Patrick K S Ng, Bianca E Amador, Emily B Roarty, Rebecca J Nagy,[...]. J Thorac Oncol 2020
23
100

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazieres, Keunchil Park, David Smith, Angel Artal-Cortes, Conrad Lewanski,[...]. Lancet 2016
100

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Matthew Dankner, April A N Rose, Shivshankari Rajkumar, Peter M Siegel, Ian R Watson. Oncogene 2018
180
100

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman,[...]. J Clin Oncol 2018
794
100

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, Shoshana Keren, Noa Popovits-Hadari, Damien Urban,[...]. J Thorac Oncol 2018
102
100


Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
100

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Tavi Nathanson, Hira Rizvi, Benjamin C Creelan, Francisco Sanchez-Vega, Arun Ahuja, Ai Ni, Jacki B Novik, Levi M B Mangarin, Mohsen Abu-Akeel,[...]. Cancer Cell 2018
581
100

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, M Pallocca, G Corleone, E Krasniqi, L Pizzuti,[...]. Ann Oncol 2020
74
100



Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
237
50

Understanding and targeting resistance mechanisms in NSCLC.
Julia Rotow, Trever G Bivona. Nat Rev Cancer 2017
463
50

DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity.
Anetta Härtlova, Saskia F Erttmann, Faizal Am Raffi, Anja M Schmalz, Ulrike Resch, Sharath Anugula, Stefan Lienenklaus, Lisa M Nilsson, Andrea Kröger, Jonas A Nilsson,[...]. Immunity 2015
431
50

Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
Qi Yang, Wei Jiang, Peng Hou. Semin Cancer Biol 2019
69
50


Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Yunfei Shi, Youming Lei, Li Liu, Shiyue Zhang, Wenjing Wang, Juan Zhao, Songhui Zhao, Xiaowei Dong, Ming Yao, Kai Wang,[...]. Cancer Med 2021
22
50

PDL1 Regulation by p53 via miR-34.
Maria Angelica Cortez, Cristina Ivan, David Valdecanas, Xiaohong Wang, Heidi J Peltier, Yuping Ye, Luiz Araujo, David P Carbone, Konstantin Shilo, Dipak K Giri,[...]. J Natl Cancer Inst 2015
382
50

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Jason P W Carey, Cansu Karakas, Tuyen Bui, Xian Chen, Smruthi Vijayaraghavan, Yang Zhao, Jing Wang, Keith Mikule, Jennifer K Litton, Kelly K Hunt,[...]. Cancer Res 2018
74
50

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Kristin J Lastwika, Willie Wilson, Qing Kay Li, Jeffrey Norris, Haiying Xu, Sharon R Ghazarian, Hiroshi Kitagawa, Shigeru Kawabata, Janis M Taube, Sheng Yao,[...]. Cancer Res 2016
442
50

Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.
Roderik M Kortlever, Nicole M Sodir, Catherine H Wilson, Deborah L Burkhart, Luca Pellegrinet, Lamorna Brown Swigart, Trevor D Littlewood, Gerard I Evan. Cell 2017
254
50

IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma.
Yuichiro Matsuoka, Hideki Nakayama, Ryoji Yoshida, Akiyuki Hirosue, Masashi Nagata, Takuya Tanaka, Kenta Kawahara, Junki Sakata, Hidetaka Arita, Hikaru Nakashima,[...]. Br J Cancer 2016
64
50

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer.
Corrin A Wohlhieter, Allison L Richards, Fathema Uddin, Christopher H Hulton, Àlvaro Quintanal-Villalonga, Axel Martin, Elisa de Stanchina, Umeshkumar Bhanot, Marina Asher, Nisargbhai S Shah,[...]. Cell Rep 2020
54
50

The Cancer Immunotherapy Revolution.
Priscilla N Kelly. Science 2018
71
50

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
Selina K Wong, Deepu Alex, Ian Bosdet, Curtis Hughesman, Aly Karsan, Stephen Yip, Cheryl Ho. Lung Cancer 2021
5
50

"Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway.
Sarah A Best, Kate D Sutherland. Cell Cycle 2018
29
50

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
Yaqi Zhao, Zheming Liu, Lan Li, Jie Wu, Huibo Zhang, Haohan Zhang, Tianyu Lei, Bin Xu. Front Microbiol 2021
7
50

The PI3K Pathway in Human Disease.
David A Fruman, Honyin Chiu, Benjamin D Hopkins, Shubha Bagrodia, Lewis C Cantley, Robert T Abraham. Cell 2017
50

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Michael J Topper, Michelle Vaz, Katherine B Chiappinelli, Christina E DeStefano Shields, Noushin Niknafs, Ray-Whay Chiu Yen, Alyssa Wenzel, Jessica Hicks, Matthew Ballew, Meredith Stone,[...]. Cell 2017
235
50

Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
Sarah A Best, David P De Souza, Ariena Kersbergen, Antonia N Policheni, Saravanan Dayalan, Dedreia Tull, Vivek Rathi, Daniel H Gray, Matthew E Ritchie, Malcolm J McConville,[...]. Cell Metab 2018
114
50

CD28 and CTLA-4 coreceptor expression and signal transduction.
Christopher E Rudd, Alison Taylor, Helga Schneider. Immunol Rev 2009
536
50

Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation.
Ambereen Ali, Ji Zhang, Shideng Bao, Irene Liu, Diane Otterness, Nicholas M Dean, Robert T Abraham, Xiao-Fan Wang. Genes Dev 2004
124
50

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
Chee Khoon Lee, Johnathan Man, Sally Lord, Matthew Links, Val Gebski, Tony Mok, James Chih-Hsin Yang. J Thorac Oncol 2017
493
50

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.
Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo. Mol Cancer 2018
171
50

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang-Min Jeon, Oded Foreman, Kuladeep Sudini, Florian Gnad, Stephane Lajoie, Naina Gour, Wayne Mitzner,[...]. Clin Cancer Res 2021
42
50

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
50

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski,[...]. Cancer Cell 2018
506
50

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
Daniel J Sargent, Silvia Marsoni, Genevieve Monges, Stephen N Thibodeau, Roberto Labianca, Stanley R Hamilton, Amy J French, Brian Kabat, Nathan R Foster, Valter Torri,[...]. J Clin Oncol 2010
995
50

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.
Francesco Facchinetti, Aurélien Marabelle, Giulio Rossi, Jean-Charles Soria, Benjamin Besse, Marcello Tiseo. J Thorac Oncol 2016
23
50

High-throughput oncogene mutation profiling in human cancer.
Roman K Thomas, Alissa C Baker, Ralph M Debiasi, Wendy Winckler, Thomas Laframboise, William M Lin, Meng Wang, Whei Feng, Thomas Zander, Laura MacConaill,[...]. Nat Genet 2007
820
50


Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Catherine Labbé, Michael Cabanero, Grzegorz J Korpanty, Pascale Tomasini, Mark K Doherty, Céline Mascaux, Kevin Jao, Bethany Pitcher, Rick Wang, Melania Pintilie,[...]. Lung Cancer 2017
121
50

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Matthew A Coelho, Sophie de Carné Trécesson, Sareena Rana, Davide Zecchin, Christopher Moore, Miriam Molina-Arcas, Philip East, Bradley Spencer-Dene, Emma Nye, Karin Barnouin,[...]. Immunity 2017
324
50

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B Solit, Matthew Hellmann,[...]. Clin Cancer Res 2018
198
50

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.
David B Shackelford, Reuben J Shaw. Nat Rev Cancer 2009
50


Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
50

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
M B Schabath, E A Welsh, W J Fulp, L Chen, J K Teer, Z J Thompson, B E Engel, M Xie, A E Berglund, B C Creelan,[...]. Oncogene 2016
185
50

Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells.
Shinichi Matsuzaki, Tamotsu Ishizuka, Takeshi Hisada, Haruka Aoki, Mayumi Komachi, Isao Ichimonji, Mitsuyoshi Utsugi, Akihiro Ono, Yasuhiko Koga, Kunio Dobashi,[...]. J Immunol 2010
23
50

Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
Thierry Landre, Gregoire Justeau, Jean-Baptiste Assié, Kader Chouahnia, Claire Davoine, Chérifa Taleb, Christos Chouaïd, Boris Duchemann. Cancer Immunol Immunother 2022
10
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.